2021
Cost-Effectiveness of Second-Line Therapies in Adult Patients with Chronic Immune Thrombocytopenia
Goshua G, Sinha P, Pischel L, Lee A, Cuker A. Cost-Effectiveness of Second-Line Therapies in Adult Patients with Chronic Immune Thrombocytopenia. Blood 2021, 138: 751. DOI: 10.1182/blood-2021-144819.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioChronic immune thrombocytopeniaOne-way deterministic sensitivity analysisPost-splenectomy sepsisTPO-RATPO-RA therapyImmune thrombocytopeniaOverall response rateTreatment pathwaysProbabilistic sensitivity analysesDeterministic sensitivity analysesResponse rateAdverse eventsASH guidelinesStandard second-line treatment optionSecond-line treatment optionSecond-line treatment strategiesEarly useComplete response rateSecond-line therapySevere septic shockThrombopoietin receptor agonistsSeptic shock mortalityHealth system perspectiveCost of surgery
2008
Early Interim FDG-PET Scan Predicts Outcome in Non-Bulky Limited Stage Hodgkin Lymphoma, but may Not Guide Use of Consolidative Radiotherapy.
Barnes J, LaCasce A, Toomey C, Hochberg E, Lee A, Canellos G, Abramson J. Early Interim FDG-PET Scan Predicts Outcome in Non-Bulky Limited Stage Hodgkin Lymphoma, but may Not Guide Use of Consolidative Radiotherapy. Blood 2008, 112: 1453. DOI: 10.1182/blood.v112.11.1453.1453.Peer-Reviewed Original ResearchInterim PET scanNegative interim PET scanPositive interim PETConsolidative radiotherapyPrimary treatment failureStage Hodgkin lymphomaLimited stage Hodgkin lymphomaEnd of therapyTreatment failureInterim PETPET scansOverall survivalHodgkin's lymphomaComplete remissionCR patientsLimited-stage Hodgkin lymphomaAchievement of CRComplete response rateCompletion of chemotherapyCycles of chemotherapyInterim FDG-PETLimited stage diseaseLimited stage patientsNegative interim PETAnthracycline-based chemotherapy